Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Get Rating) – Research analysts at SVB Leerink upped their FY2023 earnings per share (EPS) estimates for shares of Eledon Pharmaceuticals in a research note issued on Tuesday, January 10th. SVB Leerink analyst T. Smith now forecasts that the company will earn ($1.80) per share for the year, up from their prior forecast of ($2.00). The consensus estimate for Eledon Pharmaceuticals' current full-year earnings is ($2.61) per share. SVB Leerink also issued estimates for Eledon Pharmaceuticals' FY2024 earnings at ($1.87) EPS, FY2025 earnings at ($2.08) EPS and FY2026 earnings at ($1.97) EPS.

Eledon Pharmaceuticals (NASDAQ:ELDN – Get Rating) last issued its quarterly earnings results on Monday, November 14th. The company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.05).

Eledon Pharmaceuticals Stock Performance

Shares of ELDN opened at $2.87 on Thursday. The stock's 50-day simple moving average is $2.50 and its 200 day simple moving average is $2.81. The stock has a market capitalization of $39.41 million, a price-to-earnings ratio of -1.08 and a beta of 1.81. Eledon Pharmaceuticals has a 52-week low of $2.03 and a 52-week high of $5.14.

Institutional Trading of Eledon Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in ELDN. CM Management LLC increased its stake in Eledon Pharmaceuticals by 8.9% in the 3rd quarter. CM Management LLC now owns 245,000 shares of the company's stock worth $676,000 after acquiring an additional 20,000 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in Eledon Pharmaceuticals in the 3rd quarter worth about $50,000. Renaissance Technologies LLC increased its stake in Eledon Pharmaceuticals by 74.2% in the 2nd quarter. Renaissance Technologies LLC now owns 32,173 shares of the company's stock worth $79,000 after acquiring an additional 13,700 shares during the last quarter. Ensign Peak Advisors Inc increased its stake in Eledon Pharmaceuticals by 13.2% in the 3rd quarter. Ensign Peak Advisors Inc now owns 87,286 shares of the company's stock worth $241,000 after acquiring an additional 10,186 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Eledon Pharmaceuticals by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 679,243 shares of the company's stock worth $2,676,000 after acquiring an additional 9,543 shares during the last quarter. Hedge funds and other institutional investors own 45.59% of the company's stock.

Eledon Pharmaceuticals Company Profile

(Get Rating)

Eledon Pharmaceuticals, Inc, clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes.

See Also

• Get a free copy of the StockNews.com research report on Eledon Pharmaceuticals (ELDN)
• Optimism About Global Demand For Metals Boosts BHP, Other Miners
• Exxon Mobil Expects Earnings and Cash Flow to Grow
• Sorrento Therapeutics, Scilex: 2 Hot Pharma Stocks On the Move
• Is The Great Alibaba Recovery About To Begin?
• KB Home, Another Reason To Shed Home Building Stocks

Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.